Risk! Evidence! Guidelines! Fine tuning type 2 diabetes management in adults
How has the management of adult type 2 diabetes changed in recent decades?
(Episode 1)
What’s in it for me?
We value your feedback and would appreciate your help in shaping future podcasts. After listening, click here to complete the evaluation form.
Please download your CPD accreditation certificate by clicking here and record your learning reflections to support your annual professional revalidation.
GP and Director. Croydon GP Collaborative, Croydon and the James O'Riordan Medical Centre, Sutton
Consultant in Diabetes and Endocrinology, Portsmouth NHS Trust, and Honorary Professor in Diabetes and Endocrinology, Portsmouth University
This CPD-accredited podcast will cover the following topics:
- The importance of moving beyond reductions in HbA1c in people with type 2 diabetes: The role of the UK Prospective Diabetes Study (UKPDS)
- The Food and Drug Administration (FDA) and European Medicines Agency (EMA) requirements for type 2 diabetes medications to complete dedicated cardiovascular outcomes trials (CVOTs): The rosiglitazone story
- The first CVOT to demonstrate cardiovascular benefit and safety in people with type 2 diabetes: The EMPA-REG OUTCOME trial
For full prescribing and safety information in relation to individual SGLT2 inhibitors, please refer to relevant summary of product characteristics as SGLT2 inhibitor indications vary.
Abbreviations used in this podcast:
ADA, American Diabetes Association; ENT, ear, nose, throat; FDA, Food and Drug Administration; HbA1c, glycated haemoglobin; HCP, healthcare professional; MI, myocardial infarction; NICE, National Institute for Health and Care Excellence; TZD, thiazolidinedione
Podcasts 2 and 3 of this series will cover the following topics:
- The relevance of using QRISK tools in primary care to calculate and predict cardiovascular risk early in Type 2 Diabetes Progression
- The role of primary care in the early management of CRM conditions, key takeaways from the NICE Type 2 Diabetes guidelines and early initiation of SGLT2i therapy in primary care
What tools are available to assess cardiovascular risk in adult type 2 diabetes?
Speaker: Professor Ahmet Fuat
Early adoption in primary care of cardiorenal metabolic medicines in adult type 2 diabetes
Speaker: Shivani Patel
PC-GB-111729 | July 2025
The content on this website is in relation to adult patients.
Empagliflozin is not recommended in severe hepatic impairment, breastfeeding, Type 1 diabetes and is contraindicated in patients with hypersensitivity to the active ingredient or any of its excipients. Empagliflozin should be avoided in pregnancy.
Please consult the SmPC for full details regarding adverse events, monitoring requirements and interactions prior to prescribing JARDIANCE®.
- JARDIANCE® (empagliflozin) UK Summary of Product Characteristics (SmPC). Available at:
http://www.medicines.org.uk/emc/medicine/28973.
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes1
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
PC-GB-109995 V4 | October 2025